Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study.

ABSTRACT: The aim of this study was to investigate the efficacy and safety of minocycline (MIN) and favipiravir combination therapy in patients with coronavirus disease 2019 (COVID-19) admitted to our hospital in Fukui Prefecture, Japan, in March and April of 2020. In this retrospective study, a favipiravir monotherapy group (Control group, n = 9) was compared with a combined favipiravir plus MIN therapy group (MIN group, n = 12). No severe cases were present. The primary comparative endpoints evaluated were duration of fever, duration of hospitalization, duration from treatment initiation to severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR)-negative results, and changes in cytokine and chemokine production. Median duration from start of treatment to negative PCR test w

SUBMITTER: Itoh K 

PROVIDER: S-EPMC8486618 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature